- Proliferation Markers for the Differential Diagnosis of Tumor and Inflammation
[作者：van Waarde, A; Elsinga, PH,期刊：Current Pharmaceutical Design, 页码：3326-3339 , 文章类型： Article，,卷期：2008年14-31]
- FDG, the most common radiopharmaceutical for PET imaging in oncology, is not tumor-specific. Significant tracer accumulation can also occur in viral, bacterial and fungal infections, in other forms of inflammatory tissue...
- PET Imaging of the Peripheral Benzodiazepine Receptor: Monitoring Disease Progression and Therapy Response in Neurodegenerative Disorders
[作者：Doorduin, J; de Vries, EFJ; Dierckx, RA; Klein, HC,期刊：Current Pharmaceutical Design, 页码：3297-3315 , 文章类型： Review，,卷期：2008年14-31]
- It is important to gain more insight into neurodegenerative diseases, because these debilitating diseases can not be cured. A common characteristic of many neurological diseases is neuroinflammation, which is accompanied...
- Receptor Binding Ligands to Image Infection
[作者：Chianelli, M; Boerman, OC; Malviya, G; Galli, F; Oyen, WJG; Signore, A,期刊：Current Pharmaceutical Design, 页码：3316-3325 , 文章类型： Review，,卷期：2008年14-31]
- The current gold standard for imaging infection is radiolabeled white blood cells. For reasons of safety, simplicity and cost, it would be desirable to have a receptor-specific ligand that could be used for imaging infec...
- Growth Factor/Peptide Receptor Imaging for the Development of Targeted Therapy in Oncology
[作者：de Wiele, CV; Boersma, H; Dierckx, RA; De Spiegeleer, B; Van Waarde, A; Elsinga, PH,期刊：Current Pharmaceutical Design, 页码：3340-3347 , 文章类型： Review，,卷期：2008年14-31]
- Receptor imaging by means of positron emission tomography (PET) and single photon emission computerized tomography (SPECT) may non-invasively address questions that are essential to the development and the clinical appli...
- Immunoscintigraphy as Potential Tool in the Clinical Evaluation of HER2/neu Targeted Therapy
[作者：Dijkers, ECF; de Vries, EGE; Kosterink, JGW; Brouwers, AH; Hooge, MNL,期刊：Current Pharmaceutical Design, 页码：3348-3362 , 文章类型： Review，,卷期：2008年14-31]
- Many new targeted anticancer drugs have been developed. In order for these drugs to be effective, the tumor target has to be present during treatment. Currently there are only a few biomarkers available to help the physi...
|